Asundexian (BAY2433334)

Phase 3Small molecule

Asundexian (BAY2433334) is one of 34 small molecule programs targeting Transient Ischemic Attack. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transient Ischemic AttackActive, not recruiting

Atrial FibrillationActive, not recruiting

Transient Ischemic AttackPhase 3

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Asundexian (BAY2433334)

Bayer

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Brukinsa

BBeOne Medicines

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Anticoagulants

Sanofi

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Warfarin Sodium

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Completed· Bayer logo

Bayer·Phase 1·NCT05419635·27 enrolled

Transient Ischemic Attack1 trial

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

Completed· Bayer logo

Bayer·Phase 3·NCT05686070·12,327 enrolled

Atrial Fibrillation1 trial

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Terminated· Bayer logo

Bayer·Phase 3·NCT05643573·14,830 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Asundexian (BAY2433334). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Asundexian (BAY2433334) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Asundexian (BAY2433334). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Asundexian (BAY2433334)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Transient Ischemic Attack1 trial

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News